• Giuseppe TridenteEmail author


Pertuzumab (Perjeta®, Genentech) is a recombinant humanized IgG1k monoclonal antibody binding the extracellular dimerization subdomain II of the human epidermal growth factor 2 (HER2). In June 2012, FDA granted full approval for the treatment of HER2-positive metastatic breast cancer (mBC), in association with trastuzumab and docetaxel, in patients not previously treated with anti-HER2 therapy or with chemotherapy. The CHMP Committee from EMEA issued a positive opinion in December 2012 for the use of pertuzumab in the same combination therapy in HER2-positive mBC or in locally recurrent unresectable breast cancer (BC), with the same therapeutic limitations, and final approval was issued in March 2013.


Febrile Neutropenia Inflammatory Breast Cancer Mucosal Inflammation Tyrosine Kinase Pathway Triplet Combination 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

307171_1_En_33_MOESM1_ESM.xls (54 kb)
Supplementary material 1 (XLS 55 kb)


  1. 1.
    Pertuzumab (Perjeta®) BLA125409 Medical Review FDA, June 2012Google Scholar
  2. 2.
    Pertuzumab (Perjeta®) Prescribing Information Genentech, June 2012Google Scholar
  3. 3.
    Pertuzumab (Perjeta®) WC500141004 Assessment Report, EMEA Dec 2012Google Scholar
  4. 4.
    Orphanos G, Kountourakis P (2012) Targeting the HER2 receptor in metastatic breast cancer. Hematol Oncol Stem Cell Ther 5:127–137PubMedGoogle Scholar
  5. 5.
    Tsang RY, Finn RS (2012) Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. Br J Cancer 106:6–13PubMedCrossRefGoogle Scholar
  6. 6.
    Baselga J, Cortés J, Kim S-B et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109–119PubMedCrossRefGoogle Scholar
  7. 7.
    Portera CC, Walshe JM, Rosing DR et al (2008) Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with trastuzumab-insensitive human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res 14:2710–2716PubMedCrossRefGoogle Scholar
  8. 8.
    Lenihan D, Suter T, Brammer M et al (2012) Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann Oncol 23:791–800PubMedCrossRefGoogle Scholar
  9. 9.
    Gianni L, Pienkowski T, Im Y-H et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomized multicentre, open-label, phase 2 trial. Lancet Oncol 13:25–32PubMedCrossRefGoogle Scholar
  10. 10.
    Capelan M, Pugliano L, Azambuja De et al (2012) Pertuzumab: new hope for patients with HER2-positive breast cancer. Ann Oncol. doi: 10.1093/annonc/mds328 PubMedGoogle Scholar
  11. 11.
    Albanell J, Montagut C, Jones ET et al (2008) A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors. Clin Cancer Res 14:2726–2731PubMedCrossRefGoogle Scholar
  12. 12.
    Agus DB, Sweeney CJ, Morris MJ et al (2007) Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol 25:675–681PubMedCrossRefGoogle Scholar
  13. 13.
    De Bono JS, Bellmunt J, Attard G et al (2007) Open-label study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naïve patients with hormone-refractory prostate cancer. J Clin Oncol 25:257–262PubMedCrossRefGoogle Scholar
  14. 14.
    Makhija S, Amler LC, Glenn D et al (2010) Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol 28:1215–1223PubMedCrossRefGoogle Scholar
  15. 15.
    Kaye SB, Poole CJ, Dańska-Bidzińska A et al (2013) A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer. Ann Oncol 24:145–152PubMedCrossRefGoogle Scholar
  16. 16.
    Felip E, Ranson M, Cedrés S et al (2012) A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small cell lung cancer. Clin Lung Cancer 13:432–441PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  1. 1.University of VeronaVeronaItaly

Personalised recommendations